Sirolimus, but not the structurally related RAD (everolimus), enhances the negative effects of cyclosporine on mitochondrial metabolism in the rat brain

British Journal of Pharmacology

Volumn 133, Issue 6, 2001, Pages 875-885

  Serkova, Natalie ^a,b   Jacobsen, Wolfgang ^a   Niemann, Claus U ^c   Litt, Lawrence ^c   Benet, Leslie Z ^a   Leibfritz, Dieter ^b   Christians, Uwe ^a,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF BREMEN   (Germany)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF COLORADO   (United States)

Author keywords

Brain metabolism; Cyclosporine toxicity; Everolimus; Magnetic resonance spectroscopy (MRS); Mitochondrial glucose metabolism; Oxidative phosphorylation; Pharmacodynamic drug interactions; SDZ RAD; Sirolimus; Tissue distribution

Indexed keywords

4 AMINOBUTYRIC ACID; CYCLOSPORIN; EVEROLIMUS; GLUCOSE; GLUTAMIC ACID; IMMUNOSUPPRESSIVE AGENT; LACTIC ACID; NICOTINAMIDE ADENINE DINUCLEOTIDE; RAPAMYCIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN METABOLISM; BRAIN MITOCHONDRION; CONTROLLED STUDY; DRUG DETERMINATION; GLUCOSE METABOLISM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MITOCHONDRIAL RESPIRATION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; RAT; TISSUE DISTRIBUTION;

EID: 0034881393     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0704142     Document Type: Article

References (40)

1. Synergistic effects of cyclosporine and rapamycin in a chronic nephrotoxicity model
2. Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses?
3. Hyperlipidemia in renal transplant recipients treated with sirolimus (rapamycin)
4. Cyclosporin A initially as the only immunosuppressant in 34 recipients of cadaveric organs: 32 Kidneys, 2 pancreas and 2 livers
5. Automated, fast and sensitive quantification of drugs in blood using LC/LC-MS: Immunosuppressants
6. Absorption and intestinal metabolism of RAD and rapamycin in rats
7. In vitro and in situ absorption of RAD using a human intestinal cell line (Caco-2) and a single pass perfusion model in rats: Comparison with rapamycin
8. Regulation of cellular energy metabolism
9. Cyclosporine. A review of its pharmacodynamic properties, and therapeutic use in immunoregulatory disorders
10. The effect of tacrolimus (FK506) on intestinal barrier function and cellular energy production in humans
11. Cyclosporine neurotoxicity: A review
12. Newer immunosuppressive drugs: A review
13. Cyclosporine neurotoxicity
14. Combined immunosuppression with cyclosporine (Neoral) and SDZ RAD in non-human primate lung transplantation: Systematic pharmacokinetic-based trials to improve efficacy and tolerability
15. Cyclosporine A inhibits ATP net uptake of rat kidney mitochondria
16. Structure, function and regulation of pyruvate carboxylase
17. Cyclosporine
18. The synergistic effect of cyclosporine and sirolimus
19. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: A randomized multicentre study
20. Mitochondrial permeability transition in the central nervous system: Induction by calcium cycling-dependent and -independent pathways
21. Metabolism and transport of the macrolide immunosuppressant sirolimus in the small intestine
22. FK506 increases permeability in rat intestine by inhibiting mitochondrial function
23. Modulation of energy status and cytotoxicity induced by FK506 and cyclosporin A in a renal epithelial cell line
24. Relative tissue distribution of cyclosporine and sirolimus after concomitant peroral administration to the rat: Evidence for pharmacokinetic interaction
25. Trimetazidine reverses calcium accumulation and impairment of phosphorylation induced by cyclosporine A in isolated rat liver mitochondria
26. P-glycoprotein in the blood brain barrier of mice influences the brain penetration and pharmacological activity of many drugs
27. SDZ RAD, a new rapamycin derivative: Synergism with cyclosporine
28. Fine control of the conversion of pyruvate (phosphoenolpyruvate) to oxaloacetate in various species
29. Rapamune (RAPA, rapamycin, sirolimus): Mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression
30. Evaluation of the effects of immunosuppressants on neuronal and glial cells in vitro by multinuclear magnetic resonance spectroscopy
31. Tissue distribution and clinical monitoring of the novel macrolide immunosuppressant RAD and its metabolites in monkey lung transplant recipients: Interaction with cyclosporine
32. Evaluation of individual and combined neurotoxicity of the immunosuppressants cyclosporine and sirolimus by in vitro multinuclear NMR spectroscopy
33. The novel immunosuppressant RAD protects rat brain slices from cyclosporine-induced reduction of high-energy phosphates
34. Effects of the pharmacokinetic interaction between orally administered sirolimus and cyclosporine on the synergistic prolongation of heart allograft survival in rats
35. Sensitive and specific quantification of sirolimus (rapamycin) and its metabolites in blood of kidney graft recipients by HPLC/ electrospray-mass spectrometry
36. Effect of cyclosporine on oxidative phosphorylation and adenylate energy of regenerating rat liver
37. Rapamycin inhibits aldolase A expression during human lymphocyte activation
38. Cyclosporine nephrotoxicity: Attenuation by an antioxidant-inhibitor of lipid peroxidation in vitro and in vivo
39. Cyclosporine A-induced oxidative stress in rat hepatocytes